Valuation: Patrys Limited

Market Cap 17.47M 12.2M 10.9M 10.16M 9.21M 17.33M 1.16B 122M 47.63M 602M 45.82M 44.81M 1.93B P/E 2025
-0.68x
P/E 2026 -4.22x
Enterprise Value 14.11M 9.85M 8.8M 8.2M 7.44M 14M 935M 98.27M 38.47M 486M 37M 36.19M 1.56B EV / Sales 2025
1.96x
EV / Sales 2026 2,223x
Free-Float
70.71%
Yield 2025 *
-
Yield 2026 -
Current month-3.23%
1 month-11.76%
3 months-23.08%
6 months+11.11%
Current year+7.14%
1 week 0.03
Extreme 0.03
0.03
1 month 0.03
Extreme 0.03
0.04
Current year 0.02
Extreme 0.025
0.05
1 year 0.02
Extreme 0.025
0.05
3 years 0.01
Extreme 0.011987
0.13
5 years 0.01
Extreme 0.011987
0.55
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 15/02/2026
Chief Operating Officer - 31/05/2012
Corporate Secretary - 09/11/2025
Director TitleAgeSince
Director/Board Member - 16/06/2025
Chairman 64 -
Director/Board Member - 09/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
11/08/23 Expiration

Chief Executive Officer

396,132 0.0193%
11/08/23 Expiration

Chief Executive Officer

3,283 0.0002%
06/12/21 Buy

Chief Executive Officer

1,337,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+11.11%-68.75% 12.2M
-0.32%-5.97%+57.78%+74.48% 70.44B
+0.86%-13.59%+5.44%+54.17% 50.31B
+2.45%+0.49%+10.81%+36.12% 47.51B
-0.58%+0.27%+27.93%+30.76% 42.91B
-2.84%-5.72%+286.54%+530.02% 40.39B
-0.38%-3.78%+6.74%+95.25% 39.69B
-0.39%-1.48%+10.41%+43.19% 30.59B
-2.95%-12.28%+43.51%+1.51% 26.8B
-7.13%-7.02%-12.99%-14.07% 22.36B
Average -1.13%-5.40%+44.73%+78.27% 37.1B
Weighted average by Cap. -0.73%-5.61%+51.46%+100.38%

Financials

2025 2026
Net sales 829K 579K 517K 482K 437K 822K 54.93M 5.77M 2.26M 28.57M 2.17M 2.13M 91.67M 8.98K 6.28K 5.61K 5.23K 4.74K 8.91K 596K 62.59K 24.5K 310K 23.57K 23.05K 994K
Net income -3.01M -2.1M -1.88M -1.75M -1.59M -2.99M -200M -20.99M -8.22M -104M -7.9M -7.73M -333M -3.42M -2.39M -2.13M -1.99M -1.8M -3.39M -226M -23.79M -9.31M -118M -8.96M -8.76M -378M
Net Debt -742K -519K -463K -432K -391K -737K -49.22M -5.17M -2.02M -25.6M -1.95M -1.9M -82.14M -3.36M -2.35M -2.1M -1.95M -1.77M -3.33M -223M -23.41M -9.16M -116M -8.81M -8.62M -372M
Projected Income Statement - Annual - Patrys Limited
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
14/10/26 A$0.0300 0.00% 16,667
13/10/26 A$0.0300 0.00% 137,470
12/10/26 A$0.0300 0.00% 1,394,568
09/10/26 A$0.0300 -6.25% 990,343
08/10/26 A$0.0320 +6.67% 69,472